Figures & data
Figure 1. In vivo tumor growth inhibition (A) and body weight changes (B) of mice bearing SKOV-3 ovarian cancer xenografts after IT treatment with PBS(
), 2CIS2 (
), 2DTX2 (
), 2DTX1/CIS1 (
), P13L0.15O1.52D1C1 (
), 2DTX2/CIS2 (
), and P13L0.15O1.52D1C2 (
) formulations (on Days 0, 4, and 8). Each point is shown as the mean.
Figure 2. In vivo tumor growth inhibition (A) and body weight changes (B) of mice bearing SKOV-3 ovarian cancer xenografts after PT treatment with PBS (
), 2CIS1 (), 2DTX1 (), 2DTX1/CIS1 (), and P13L0.15O1.52D1C1 () formulations (on Days 0, 4, and 8). Each point is shown as the mean ± SD (n = 5).
Figure 3. In vivo pharmacokinetic profiles of DTX (A) and CIS (B) after being treated with 2DTX2 (IV,
) through a tail vein and 2DTX2 (SC,), 2CIS2 (SC,), 2DTX2/CIS2 (SC,), P13L0.15O1.52D1C1 (SC,), 2DTX1/CIS1 (SC,), and P13L0.15O1.52D1C1 (SC, ). Data are expressed as the mean ± SD (n = 3 or 4).
Table 1. Pharmacokinetic parameter estimations of DTX in plasma of normal balb/c mice after being treated with 2DTX2 (4 mg/kg, IV) through a tail vein and 2DTX2 (4 mg/kg, SC), 2DTX2/CIS2 (4 mg/kg each, SC), P13L0.15O1.52D2C2 (4 mg/kg each, SC), 2DTX1/CIS1 (2 mg/kg each, SC), and P13L0.15O1.52D1C1 (2 mg/kg each, SC).
Table 2. Pharmacokinetic parameter estimations of CIS in plasma of normal balb/c mice after being treated with 2CIS2 (4 mg/kg, IV) through a tail vein and 2CIS2 (4 mg/kg, SC), 2DTX2/CIS2 (4 mg/kg each, SC), P13L0.15O1.52D2C2 (4 mg/kg each, SC), 2DTX1/CIS1 (2 mg/kg each, SC), and P13L0.15O1.52D1C1 (2 mg/kg each, SC).
Figure 4. Tissue distributions of DTX (A) and CIS (B) 72 h after IV and IT administration of 2DTX2 (4 mg/kg, IV), 2CIS2 (4 mg/kg, IV), 2DTX2 (4 mg/kg, IT), 2CIS2 (4 mg/kg, IT), 2DTX1/CIS1 (2 mg/kg each, IV), 2DTX1/CIS1 (2 mg/kg each, IT), P13L0.15O1.52D1C1 (2 mg/kg each, IT), 2DTX2/CIS2 (4 mg/kg each, IV), 2DTX2/CIS2 (4 mg/kg each, IT), and P13L0.15O1.52D2C2 (4 mg/kg each, IT) into SKOV-3 tumor-bearing Balb/c nude mice. Data are expressed as the mean ± SD (n = 4).
